Literature DB >> 23700208

Comment on the editorial of Sautter-Bihl et al. in Strahlentherapie und Onkologie 2013 189:105-110.

T Junginger, C A Maurer, R Ruppert, H Ptok, J Strassburg.   

Abstract

Mesh：

Year:  2013        PMID： 23700208     DOI： 10.1007/s00066-013-0353-y

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN： 0179-7158            Impact factor:   3.621


× No keyword cloud information.
  19 in total

1.  [Quality indicators of diagnosis and therapy in MRI-based neoadjuvant radiochemotherapy for rectal cancer - interim analysis of a Prospective Multicentre Observational Study (OCUM)].

Authors:  R Ruppert; H Ptok; J Strassburg; C A Maurer; T Junginger; S Merkel; P Hermanek
Journal:  Zentralbl Chir       Date:  2012-06-14       Impact factor: 0.942

Review 2.  Neoadjuvant therapy in rectal cancer.

Authors:  Fergal J Fleming; Lars Påhlman; John R T Monson
Journal:  Dis Colon Rectum       Date:  2011-07       Impact factor: 4.585

3.  Preoperative chemoradiation may not always be needed for patients with T3 and T2N+ rectal cancer.

Authors:  Matteo Frasson; Eduardo Garcia-Granero; Desamparados Roda; Blas Flor-Lorente; Susana Roselló; Pedro Esclapez; Carmen Faus; Samuel Navarro; Salvador Campos; Andrés Cervantes
Journal:  Cancer       Date:  2011-01-24       Impact factor: 6.860

4.  Accuracy of magnetic resonance imaging in rectal cancer depends on location of the tumor.

Authors:  Frédérique Peschaud; Charles-Anché Cuenod; Stéphane Benoist; Catherine Julié; Alain Beauchet; Nathalie Siauve; Florence Taieb-Kasbi; Christophe Penna; Bernard Nordlinger
Journal:  Dis Colon Rectum       Date:  2005-08       Impact factor: 4.585

5.  The impact of the introduction of total mesorectal excision on local recurrence rate and survival in rectal cancer: long-term results.

Authors:  C A Maurer; P Renzulli; C Kull; S A Käser; L Mazzucchelli; A Ulrich; M W Büchler
Journal:  Ann Surg Oncol       Date:  2011-02-05       Impact factor: 5.344

6.  Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years.

Authors:  Rolf Sauer; Torsten Liersch; Susanne Merkel; Rainer Fietkau; Werner Hohenberger; Clemens Hess; Heinz Becker; Hans-Rudolf Raab; Marie-Therese Villanueva; Helmut Witzigmann; Christian Wittekind; Tim Beissbarth; Claus Rödel
Journal:  J Clin Oncol       Date:  2012-04-23       Impact factor: 44.544

7.  Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial.

Authors:  Willem van Gijn; Corrie A M Marijnen; Iris D Nagtegaal; Elma Meershoek-Klein Kranenbarg; Hein Putter; Theo Wiggers; Harm J T Rutten; Lars Påhlman; Bengt Glimelius; Cornelis J H van de Velde
Journal:  Lancet Oncol       Date:  2011-05-17       Impact factor: 41.316

8.  Preoperative high-resolution magnetic resonance imaging can identify good prognosis stage I, II, and III rectal cancer best managed by surgery alone: a prospective, multicenter, European study.

Authors:  Fiona G M Taylor; Philip Quirke; Richard J Heald; Brendan Moran; Lennart Blomqvist; Ian Swift; David J Sebag-Montefiore; Paris Tekkis; Gina Brown
Journal:  Ann Surg       Date:  2011-04       Impact factor: 12.969

Review 9.  [Rectal cancer. How much radiotherapy do surgery patients need?].

Authors:  A Ulrich; J Weitz; M W Büchler
Journal:  Chirurg       Date:  2009-04       Impact factor: 0.955

Review 10.  Communicating evidence for participatory decision making.

Authors:  Ronald M Epstein; Brian S Alper; Timothy E Quill
Journal:  JAMA       Date:  2004-05-19       Impact factor: 56.272
View more
  1 in total

1.  Adenocarcinomas of the upper third of the rectum and the rectosigmoid junction seem to have similar prognosis as colon cancers even without radiotherapy, SAKK 40/87.

Authors:  S A Käser; J Froelicher; Q Li; S Müller; U Metzger; M Castiglione; U T Laffer; C A Maurer
Journal:  Langenbecks Arch Surg       Date:  2014-08-28       Impact factor: 3.445
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.